Department of Biochemical Diagnostics, Medical University of Bialystok, Poland.
Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Poland.
Cancer Control. 2020 Jan-Dec;27(1):1073274820903384. doi: 10.1177/1073274820903384.
Colorectal cancer (CRC) is one of the leading causes of cancer-related death. It is the second most frequently diagnosed malignancy in Europe and third worldwide. Colorectal malignancies diagnosed at an early stage offer a promising survival rate. However, advanced tumors often present distant metastases even after the complete resection of a primary tumor. Therefore, novel biomarkers of CRC are sorely needed in the diagnosis and prognosis of this common malignancy. A family of chemokines are composed of small, secreted proteins. They are best known for their ability to stimulate the migration of several cell types. Some investigations have indicated that chemokines are involved in cancer development, including CRC. This article presents current knowledge regarding chemokines and their specific receptors in CRC progression. Moreover, the prime aim of this review is to summarize the potential role of these proteins as biomarkers in the diagnosis and prognosis of CRC.
结直肠癌（CRC）是癌症相关死亡的主要原因之一。它是欧洲第二大常见的恶性肿瘤，也是全球第三大常见的恶性肿瘤。早期诊断的结直肠恶性肿瘤提供了有希望的生存率。然而，即使在原发性肿瘤完全切除后，晚期肿瘤也常发生远处转移。因此，在这种常见恶性肿瘤的诊断和预后中非常需要新型 CRC 生物标志物。趋化因子家族由小的分泌蛋白组成。它们最著名的作用是能够刺激几种细胞类型的迁移。一些研究表明，趋化因子参与了癌症的发展，包括 CRC。本文介绍了趋化因子及其在 CRC 进展中的特定受体的最新知识。此外，本文的主要目的是总结这些蛋白作为 CRC 诊断和预后生物标志物的潜在作用。
